Conduct study P218
Ended Awarded Last action
- Contract number
- 75N93022F00002
- Awardee
-
Bioqual, Inc. UEI CK9LGQ7EBNN8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $287,788
Award facts
- Contract value 37% obligated
-
- $287,787.63 Current, with exercised options
- $782,160.63 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Funding Only Action | -$296,432 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $584,220 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $782,160.63 to Bioqual, Inc. for the conduct of Study P218. This unilateral modification (Amendment 2) updates Federal Procurement Data System (FPDS) reporting processes to ensure compliance with a Presidential Memorandum regarding radical transparency about wasteful spending. The contract utilizes a cost-plus-fixed-fee pricing structure with a completion date of June 4, 2024. Bioqual, Inc., a Rockville, Maryland-based biomedical research services company, serves as the prime contractor. This delivery order is issued under the Simian Vaccine Evaluation Units indefinite delivery vehicle and represents no set-aside designation, indicating open competition.
Bioqual, Inc. specializes in providing advanced scientific research support to federal agencies, with particular expertise in animal research models, laboratory analysis, and experimental studies supporting infectious disease research and vaccine development. The company maintains significant indefinite delivery contracts with NIAID, including a $146.3 million single-award indefinite delivery contract focused on animal model development for evaluating countermeasures against infectious diseases and a $545 million multiple-award indefinite delivery/indefinite quantity contract supporting comprehensive research services across NIAID's divisions. This delivery order leverages Bioqual's established capabilities and infrastructure within NIAID's research infrastructure portfolio.
Quick answers
Who was awarded contract 75N93022F00002?
75N93022F00002 was awarded to Bioqual, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 27, 2022.
How much is contract 75N93022F00002 worth?
The government has obligated $287,788 on 75N93022F00002. Its potential value, with all options, is $782,161.
Is contract 75N93022F00002 an order under another contract?
Yes. 75N93022F00002 is a delivery order under 75N93020D00006, an indefinite delivery contract, on Simian Vaccine Evaluation Units.
Was contract 75N93022F00002 competed?
The extent of competition for 75N93022F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award